– Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target…
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with…
WARRINGTON, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology…
FORT WORTH, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage…
Powered by Enzo’s LoopRNA™ ISH technology, a new platform designed for superior sensitivity in detection…
SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc….
Study met both co-primary endpoints and all secondary endpoints At week eight, 67.3% of individuals…
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (Celularity), a…
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology…
BURNABY, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) — Qu Biologics Inc., a clinical stage…
Results highlight a potential novel treatment for diabetic and other retinopathies Unique Wnt-mediated mechanism increases…
The first two Fanconi Anemia patients receiving JSP191 achieved 100% donor chimerism JSP191 safe to…
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a…
AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) — Secure Transfusion Solutions (STS), a private life…
SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision…
SYDNEY, AUSTRALIA, Sept. 26, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…
~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon…
MONTREAL, Sept. 26, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a…
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage…
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…